CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM135088
Első szerző:Horst, Ludwig Jesse
Cím:6-Mercaptopurine vs. Mycophenolate Mofetil in Autoimmune Hepatitis and Azathioprine Intolerance : a Multicenter Study / Horst Ludwig Jesse, Fierenz Alexander, Canhao Bernardo, Efe Cumali, Díaz-González Álvaro, Hartl Johannes, Hübener Sina, Kovats Patricia Julianna, Liberal Rodrigo, Lohse Ansgar Wilhelm, Londono Maria-Carlota, Lytvyak Ellina, Macedo Guilherme, Madaleno Joao, Munoz Beatriz Mateos, Montano-Loza Aldo J., Morris Sean M., Pallotta Dante Pio, Papp Maria, Sebode Marcial, Trivedi Palak Jitendrakumar, Oo Ye Htun, Schramm Christoph
Dátum:2026
ISSN:1542-3565 1542-7714
Megjegyzések:Background & Aims: Azathioprine (AZA) and corticosteroids are the recommended standard therapy for autoimmune hepatitis (AIH); however, a significant proportion of patients discontinue AZA due to intolerance. Although guidelines propose 6-mercaptopurine (6-MP) and mycophenolate mofetil (MMF) as alternatives, there is a lack of data on 6-MP and no comparative studies in AIH. We aimed to compare the efficacy and safety of 6-MP and MMF as second-line therapies in patients intolerant to AZA. Methods: This multicenter retrospective cohort study involved AIH patients from eleven tertiary care centers across Europe and Canada who were intolerant to AZA and subsequently switched to either 6- MP or MMF as second-line interventions. Data on biochemical response, adverse effects, and treatment duration of second-line therapies were collected and analyzed, incorporating propensity score matching to validate the biochemical response. Results: We included 211 AIH patients (81% female; median age: 54 years (IQR: 39?63 years)) with a median follow-up of 60 months (IQR: 31?105 months). MMF was better tolerated than 6-MP (89% vs. 67%; p < 0.001). Among patients who continued second-line treatment, no statistically significant difference in complete biochemical response rates was observed between 6-MP and MMF (61% and 66%, respectively, at the last follow-up). Conclusions: Both 6-MP and MMF were capable of maintaining biochemical response in patients with AIH who were intolerant to AZA, with no clear evidence of inferiority of either treatment. While MMF was generally better tolerated, 6-MP may present a safe and effective treatment option in women of reproductive age. In addition, therapy with 6-MP enables clinicians to monitor drug metabolite levels, titrate dosages, and monitor adherence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
AIH
Second-line therapy
Azathioprine intolerance
Immunosuppression
Megjelenés:Clinical Gastroenterology and Hepatology. - [Epub ahead of print] (2026). -
További szerzők:Fierenz, Alexander Canhão, Bernardo Efe, Cumali Díaz-González, Álvaro Hartl, Johannes Hübener, Sina Kováts Patrícia (1995-) Liberal, Rodrigo Lohse, Ansgar W. Londono, Maria-Carlota Lytvyak, Ellina Macedo, Guilherme Madaleno, João Munoz, Beatriz Mateos Montano-Loza, Aldo J. Morris, Sean M. Pallotta, Dante Pio Papp Mária (1975-) (belgyógyász, gasztroenterológus) Sebode, Marcial Trivedi, Palak Jitendrakumar Oo, Ye Htun Schramm, Christoph
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM132974
Első szerző:Ma, Ann
Cím:Real-world Use of Terlipressin in Cirrhosis and Acute Kidney Injury : Frequent Use Beyond Hepatorenal Syndrome / Ma Ann T., Juanola Adria, Patidar Kavish R., Barone Anna, Incicco Simone, Kulkarni Anand V., Verma Nipun, Lange Christian M., Xie Qing, Alessandria Carlo, Cerda Reyes Eira, Maiwall Rakhi, Kim Jeong Han, Marciano Sebastián, Farias Alberto Queiroz, Toledo Claudio, Nardelli Silvia, Vorobioff Julio D., Roblero Juan Pablo, Thévenot Thierry, Papp Maria, Maan Raoel, Solé Cristina, Cordova-Gallardo Jacqueline, Simonetto Douglas A., Fouad Yasser, Balcar Lorenz, Raevens Sarah, Nabilou Puria, Caraceni Paolo, Merli Manuela, Presa José, Laleman Wim, Krag Aleksander, Bruns Tony, Pereira Gustavo, Mattos Angelo Z., Arab Juan Pablo, Wentworth Brian, Abdelkader Nadia Abdelaaty, Wong Yu Jun, Kim Sung-Eun, Roux Olivier, Takkenberg R. Bart, Galante Antonio, Goncalves Luciana Lofego, Pyrsopoulos Nikolaos T., Pérez Hernández José Luis, Asrani Sumeet K., Torre Aldo, Díaz-Ferrer Javier, Orman Eric S., Perricone Giovanni, Gadano Adrian, Ivashkin Vladimir, Fassio Eduardo, Marino Mónica, Vargas Victor, Rabinowich Liane, Montes Pedro, Mohammed Abdulsemed, Carrera Enrique, Cabrera María Cecilia, Girala Marcos, Samant Hrishikesh, Madaleno Joao, Kim W. Ray, Ferreira Carlos Noronha, Allegretti Andrew S., Sarin Shiv K., Gines Pere, Angeli Paolo, Sola Elsa, Piano Salvatore, International Club of Ascites GLOBAL AKI team
Dátum:2026
ISSN:1542-3565 1542-7714
Megjegyzések:BACKGROUND & AIMS: Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI) but is likely used outside this primary indication in clinical practice. We aimed to investigate realworld practice patterns on the use of terlipressin in AKI in cirrhosis. METHODS: International prospective study including patients hospitalized for decompensated cirrhosis. This was a subgroup analysis of patients who received terlipressin to treat AKI. Primary outcome was AKI resolution. Secondary outcomes were respiratory failure and 28-day mortality. RESULTS: Among 1456 patients with AKI, 243 (17%) received terlipressin. Terlipressin was predominantly administered as a continuous infusion (75%). The AKI phenotype was HRS-AKI in 50%, acute tubular necrosis (ATN) in 17%, hypovolemic in 25%, and other in 8%. AKI resolution occurred in 49% of the patients, and was lowest in ATN (29%), followed by HRS-AKI (51%) and hypovolemic (63%). ATN was independently associated with lack of AKI resolution (odds ratio, 2.77; 95% confidence interval, 1.24?6.54; P ? .02). De novo respiratory failure occurred in 20% of patients. There were no significant differences in the amount of albumin received nor acute-on-chronic liver failure grade between those who did and did not develop respiratory failure. The presence of pneumonia independently predicted respiratory failure (odds ratio, 7.80; 95% confidence interval, 2.43?26.95; P < .001). Mortality rate at 28 days was 36%; ATN and hospital-acquired AKI independently predicted 28-day mortality. CONCLUSIONS: Terlipressin is often used for treatment of AKI outside its primary indication of HRS-AKI. Compared with patients with HRS-AKI, response to terlipressin is significantly lower in patients with ATN, in whom the risks may outweigh the benefits. Respiratory failure is common but does not seem to be driven by the amount of albumin received nor acute-on-chronic liver failure grade.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Hepatorenal Syndrome
Mortality
Respiratory Failure
Vasoconstrictor
Megjelenés:Clinical Gastroenterology and Hepatology. - 24 : 4 (2026), p. 1079-1091. -
További szerzők:Juanola, Adria Patidar, Kavish R. Barone, Anna Incicco, Simone Kulkarni, Anand V. Verma, Nipun Lange, Christian M. Xie, Qing Alessandria, Carlo Cerda, Eira Maiwall, Rakhi Kim, Jeonghan Marciano, Sebastian Farias, Alberto Queiroz Toledo, Claudio Nardelli, Silvia Vorobioff, Julio D. Roblero, Juan Pablo Thevenot, Thierry Papp Mária (1975-) (belgyógyász, gasztroenterológus) Maan, Raoel Sole, Cristina Cordova-Gallardo, Jacqueline Simonetto, Douglas A. Fouad, Yasser Balcar, Lorenz Raevens, Sarah Nabilou, Puria Caraceni, Paolo Merli, Manuela Presa, José Laleman, Wim Krag, Aleksander Bruns, Tony Pereira, Gustavo Mattos, Angelo Z. Arab, Juan Pablo Wentworth, Brian Abdelkader, Nadia Abdelaaty Wong, Yu Jun Kim, Sung-Eun Roux, Olivier Takkenberg, Bart Galante, Antonio Goncalves, Luciana Lofego Pyrsopoulos, Nikolaos T. Pérez Hernández, José Luis Asrani, Sumeet K. Torre, Aldo Díaz-Ferrer, Javier Orman, Eric S. Perricone, Giovanni Gadano, Adrian Ivashkin, Vladimir Fassio, Eduardo Marino, Monica Vargas, Victor Rabinowich, Liane Montes, Pedro Mohammed, Abdulsemed Carrera, Enrique Cabrera, María Cecilia Girala, Marcos Samant, Hrishikesh Madaleno, João Kim, W. Ray Ferreira, Carlos Noronha Allegretti, Andrew S. Sarin, Shiv K. Ginès, Pere Angeli, Paolo Solà, Elsa Piano, Salvatore International Club of Ascites GLOBAL AKI team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM081815
035-os BibID:(WoS)000552446400014 (Scopus)85084968025
Első szerző:Pape, Simon
Cím:Rapid Response to Treatment of Autoimmune Hepatitis Associated with Remission at 6 and 12 Months / Simon Pape, Tom J. G. Gevers, Jan Maarten Vrolijk, Bart van Hoek, Gerd Bouma, Carin M. J. van Nieuwkerk, Richard Taubert, Elmar Jaeckel, Michael P. Manns, Maria Papp, Nora Sipeki, Felix Stickel, Cumali Efe, Ersan Ozaslan, Tugrul Purnak, Frederik Nevens, Dominik J. N. Kessener, Alisan Kahraman, Heiner Wedemeyer, Johannes Hartl, Christoph Schramm, Ansgar W. Lohse, Joost P. H. Drenth, Michael A. Heneghan
Dátum:2020
ISSN:1542-3565 1542-7714
Megjegyzések:Background & Aims: Changes in serum levels of transaminases immediately after initiation of treatment for autoimmune hepatitis (AIH) might be associated with biochemical markers of remission and liver-related events. We assessed the outcomes of patients with vs without rapid responses to treatment of AIH in a large international cohort. Methods: We performed a retrospective cohort study, collecting data from 2 independent cohorts of adults with AIH from 12 centers in 7 countries in Europe. We collected information on patient demographics; serologic, histologic, and biochemical analyses; and treatment. We used a receiver operating characteristic curve and Youden index to calculate the optimal percentage decrease in level of aspartate aminotransferase (AST) after 8 weeks of treatment that associated with normalization of transaminase levels after 26 weeks of treatment with predniso(lo)ne (primary outcome) in the first (discovery) cohort (n = 370). We evaluated the results in the second (validation) cohort (n = 370). Secondary outcomes were liver-related death or transplantation. We performed univariate and multivariable logistic and Cox regression with correction for confounders. Results: A significant decrease in level of AST after 8 weeks of treatment was significantly associated with normalization of transaminase levels at 26 and 52 weeks ( P <.001); a decrease of more than 80% in level of AST was associated with optimal normalization. In both cohorts, rapid responders (?80% decrease in level of AST after 8 weeks) were more likely to achieve normalization of transaminases at 26 and 52 weeks when compared to non-rapid responders. Rapid responders in the discovery cohort had lower risk of liver-related death or transplantation (adjusted hazard ratio 0.18; 95% CI 0.05?0.63; P =.007), although this was not confirmed in the validation cohort. Results from measurement of alanine aminotransferase did not differ significantly from those of AST for the primary outcome. Slow responders (without normalization of transaminases after 1 year) had the highest risk of liver transplantation or liver-related death. Conclusions: In a retrospective study of patients with AIH, we found that a rapid response to treatment, based on level of AST after 8 weeks, associates with normalization of transaminase levels in the following year. Patients with a rapid response also have a lower risk of liver-related death or transplantation than patients without this rapid response.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Induction therapy,
prognostic factor,
liver enzyme,
Megjelenés:Clinical Gastroenterology and Hepatology. - 18 : 7 (2020), p. 1609-1617. -
További szerzők:Gevers, Tom J. G. Maarten Vrolijk, Jan Hoek, Bart van Bouma, Gerd Nieuwkerk, Carin M. J. van Taubert, Richard Jaeckel, Elmar Manns, Michael P. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Sipeki Nóra (1987-) (általános orvos) Stickel, Felix Efe, Cumali Ozaslan, Ersan Purnak, Tugrul Nevens, Frederik Kessener, Dominik J. N. Kahraman, Alisan Wedemeyer, Heiner Hartl, Johannes Schramm, Christoph Lohse, Ansgar W. Drenth, Joost P. H. Heneghan, Michael A.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM077050
035-os BibID:(WoS)000482217300030 (Scopus)85065040027
Első szerző:Pape, Simon
Cím:Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis / Simon Pape, Tom J. G. Gevers, Michail Belias, Ilyas F. Mustafajev, Jan Maarten Vrolijk, Bart van Hoek, Gerd Bouma, Carin M. J. van Nieuwkerk, Johannes Hartl, Christoph Schramm, Ansgar W. Lohse, Richard Taubert, Elmar Jaeckel, Michael P. Manns, Maria Papp, Felix Stickel, Michael A. Heneghan, Joost P. H. Drenth
Dátum:2019
ISSN:1542-3565 1542-7714
Megjegyzések:BACKGROUND & AIMS: Patients with autoimmune hepatitis (AIH) commonly receive induction therapy with predniso(lo)ne followed by maintenance therapy with azathioprine. European Association for Study of the Liver clinical practice guidelines advise a predniso(lo)ne dose range of 0.50-1 mg/kg/day, which leaves room for practice variation. We performed a multicenter study to determine the efficacy of different dose ranges of predniso(lo)ne induction therapy in a large European cohort of patients with AIH. METHODS: We performed a retrospective cohort study using a comparative effectiveness design. We collected data from 451 adults with AIH who began treatment from 1978 through 2017 at 9 centers in 5 European countries. We assigned patients to a high-dose group (initial predniso(lo)ne dose ?0.50 mg/kg/day; n=281) or a low-dose group (<0.50 mg/kg/day; n=170). Logistic regression was performed to determine difference in outcomes between the groups. The primary outcome was normal serum levels of transaminases at 6 months after initiation of therapy. RESULTS: There was no significant difference in rates of normalization of transaminases between the high-dose predniso(lo)ne group and the low-dose group (70.5% vs 64.7%; P=.20). After multivariable logistic regression with correction for confounders, there was no difference in the likelihood of normalization of transaminases between the groups (odds ratio, 1.21; 95% CI, 0.78 - 1.87; P=.38). Patients given an initial high dose of predniso(lo)ne received more predniso(lo)ne over time than patients started on a lower dose (median doses over 6 months: 3780 mg vs 2573 mg) (P<.01). CONCLUSIONS: In a retrospective study of patients with AIH in Europe, we found that the dose of predniso(lo)ne to induce remission in patients with AIH is less relevant than assumed. An initial predniso(lo)ne dose below 0.50 mg/kg/day substantially decreases unnecessary exposure to predniso(lo)ne in patients with AIH.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
autoimmune hepatitis
EASL guidelines
ALT
AST
IgG
corticosteroid
induction therapy
cirrhosis
prednison
prednisolon
Megjelenés:Clinical Gastroenterology and Hepatology. - 17 : 10 (2019), p. 2068-2075.e2. -
További szerzők:Gevers, Tom J. G. Belias, Michail Mustafajev, Ilyas F. Vrolijk, Jan Maarten van Hoek, Bart Bouma, Gerd van Nieuwkerk, Carin M. J. Hartl, Johannes Schramm, Christoph Lohse, Ansgar W. Taubert, Richard Jaeckel, Elmar Manns, Michael P. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Stickel, Felix Heneghan, Michael A. Drenth, Joost P. H.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM055764
Első szerző:Sandborn, William J.
Cím:A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease / William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Wenjin Wang, Wojciech Niezychowski, Study A3921043 Investigators
Dátum:2014
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Gastroenterology and Hepatology. - 12 : 9 (2014), p. 1485-1493. -
További szerzők:Ghosh, Subrata Panes, Julian Vranic, Ivana Wang, Wenjin Niezychowski, Wojciech Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Study A3921043 Investigators
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM013068
Első szerző:Zöld Éva (belgyógyász)
Cím:Hydatid disease of the liver and associated hepatocellular carcinoma / Éva Zöld, Zsolt Barta, Margit Zeher
Dátum:2005
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Gastroenterology and Hepatology. - 3 : 8 (2005), p. 35. -
További szerzők:Barta Zsolt (1964-) (belgyógyász, gasztroenterológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.